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Abstract
The interplay between the innate and acquired immune systems
in chronic inflammation is not well documented. We have
investigated the mechanisms of inflammation in murine
zymosan-induced arthritis (ZIA) in the light of recent data on the
roles of Toll-like receptor 2 (TLR2) and Dectin-1 in the activation
of monocyte/macrophages by zymosan. The severity of
inflammation, joint histology, lymphocyte proliferation and
antibody production in response to zymosan were analyzed in
mice deficient in TLR2 and complement C3, and the effects of
Dectin-1 inhibition by laminarin were studied. In comparison with
wild-type animals, TLR2-deficient mice showed a significant
decrease in the early (day 1) and late phases (day 24) of joint
inflammation. C3-deficient mice showed no differences in
technetium uptake or histological scoring. TLR2-deficient mice
also showed a significant decrease in lymph node cell
proliferation in response to zymosan and a lower IgG antibody
response to zymosan at day 25 in comparison with wild-type
controls, indicating that TLR2 signalling has a role in the
development of acquired immune responses to zymosan.
Although laminarin, a soluble β-glucan, was able to significantly
inhibit zymosan uptake by macrophages in vitro, it had no effect
on ZIA in vivo. These results show that ZIA is more prolonged
than was originally described and involves both the innate and
acquired immune pathways. C3 does not seem to have a major
role in this model of joint inflammation.
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Introduction
Zymosan, a polysaccharide from the cell wall of Saccharo-
myces cerevisiae, is composed primarily of glucan and
mannan residues [1]. In vitro, it has served as a model for
the study of innate immune responses, because it is capa-
ble of stimulating inflammatory cytokine production [2] and
can activate complement in the absence of immunoglobu-
lins [3]. Zymosan is recognized and phagocytosed princi-
pally by monocytes and macrophages and leads to cellular
activation [4]. Zymosan-induced arthritis (ZIA) in mice was
first described by Keystone in 1977 [5]. Arthritis was
induced by intra-articular injection of zymosan and was
thought to be mediated by activation of the alternative path-
way of complement and the release of lysosomal hydro-
lases from activated macrophages [6].
The recent discovery of pattern recognition receptors and
their role in innate immunity has led to a re-evaluation of our
concepts of zymosan-induced inflammation. Toll-like recep-
tors (TLRs) are a family of type 1 transmembrane proteins
that consists of an extracellular leucine-rich repeat domain
and a cytoplasmic domain homologous to the cytoplasmic
domain of the human interleukin 1 (IL-1) receptor [7]. The
ligands of TLR2 include lipopeptides and peptidoglycan
[8,9], and TLR2 is a receptor for zymosan, acting in collab-
oration with CD14 and TLR6 [2,10]. Ligand binding to
TLRs induces the activation of NF-κB and the production
of the inflammatory cytokines IL-1, IL-6, IL-8, and IL-18 as
well as the expression of the co-stimulatory molecule B7.1
[7]. Additionally, zymosan is able to induce maturation of
dendritic cells in vitro and to stimulate their production of
IL-2 [11,12], providing evidence for a link between the
innate and the adaptive immune responses.
The inflammatory response triggered by zymosan is linked
to its phagocytosis, a process that is mediated by a set of
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different receptors from the TLRs. The non-opsonic recog-
nition of zymosan by macrophages is mediated by Dectin-
1. Dectin-1 is a type 2 membrane receptor with an extracel-
lular C-type lectin-like domain fold and a cytoplasmic immu-
noreceptor tyrosine-based activation motif [13] and is
expressed on macrophages, dendritic cells and neutrophils
[14-16]. Dectin-1 mediates the binding of Saccharomyces
cerevisiae and Candida albicans in a β-glucan-dependent
manner and may also have a pro-inflammatory function
[17].
In the light of the above findings, we have re-investigated
ZIA to elucidate the roles of the innate and adaptive
immune responses in this model and to compare the
effects of TLR2 deficiency and complement C3 deficiency.
The role of Dectin-1 in zymosan-induced inflammation was
also investigated. Our results indicate that TLR2 is the
major pathway of pro-inflammatory signalling in ZIA and is
necessary for the development of specific immune
responses to zymosan.
Materials and methods
Animals
C3-deficient mice (C3-/-) on a C57bl/6 background were
generated by Professor M Botto [18]. TLR2-deficient mice
(TLR2-/-) on a C57bl/6 background were provided by Dr
Kiyoshi Takeda (Department of Host Defense, Research
Institute for Microbial Diseases, Osaka University) [19].
Wild-type (WT) C57bl/6 mice were purchased from
Charles River (L'Arbresle, France). All mice were bred in
our animal house facility. Double knockout and double WT
mice were generated by mating TLR2-/- and C3-/- mice. The
genotypes of all mice used were confirmed by polymerase
chain reaction analysis of genomic DNA extracted from
mice tails. The primer sequences used were as follows:
TLR2 sense, 5' -GTTCTCCCAGCATTTAAAATCATT-3' ;
TLR2 antisense, 5' -GTCTCCAGTTTGGGAAAAGAACC-
3' ; TLR2 NEO antisense, 5' -CGACACAGCTGCGCAAG-
CAAC-3' ; C3 sense, 5' -CTTCATAGACTGCT-
GCAACCA-3' ; C3 antisense, 5' -
AACCAGCTCTGTGGGAAGTG-3' ; C3 NEO antisense,
5' -AAGGGACTGGCTGCTATTGG-3'.
Induction of ZIA
Zymosan A from Saccharomyces cerevisiae (Sigma, St
Louis, MO, USA) (300 mg) was resuspended in 10 ml of
endotoxin-free saline, boiled and homogenized by sonic
emulsification. The suspension was autoclaved and stored
in aliquots at -20°C. Arthritis was induced by intra-articular
injection of 180 µg (6 µl) of zymosan through the suprapa-
tellar ligament into the joint cavity. In specified experiments,
the contralateral knee was injected with an equal amount of
sterile saline (6 µl) as control.
Laminarin was co-injected at a dose of either 500 µg or
100 µg together with 180 µg of zymosan into the knee
joint.
Approval was obtained from the local animal health commit-
tee for these experiments.
Isotopic quantification of joint inflammation in vivo
Joint inflammation was measured by 99mTc uptake in the
knee joint as described [20]. Mice were sedated by the
intra-peritoneal administration of sodium pentobarbital (50
mg/kg) and then injected subcutaneously in the neck
region with 10 µCi of 99mTc. The accumulation of the iso-
tope in the knee was determined by external gamma-count-
ing after 15 min. The ratio of 99mTc uptake in the inflamed
arthritic knee to 99mTc uptake in the contralateral control
knee was calculated. A ratio higher than 1.1:1 indicated
joint inflammation.
Histological grading of arthritis
Mice were killed at day 8 and at day 25. Knees were dis-
sected and fixed for 2 weeks in 10% buffered formalin.
Fixed tissues were decalcified for 2 weeks in 15% EDTA,
dehydrated and embedded in paraffin. Sagittal sections (5
µm) of the whole knee joint were stained with safranin-O
and counterstained with fast green/iron hematoxylin. Histo-
logical sections were graded by two observers unaware of
animal genotype or treatment. Synovial cell infiltrate and
exudate were scored from 0 (no cells) to 6 (maximum
number of inflammatory cells). Cartilage proteoglycan
depletion (damage), reflected by a loss of safranin-O stain-
ing intensity, was scored on a scale from 0 (fully stained
cartilage) to 6 (totally unstained cartilage) in proportion to
severity. For each histopathological measure the score
(mean ± SEM) of all slides was calculated.
T cell proliferation assay
Mice were killed in accordance with the experimental pro-
tocol. Inguinal lymph nodes were removed and single-cell
suspensions were incubated in RPMI supplemented with
2-mercaptoethanol, penicillin, streptomycin and 1% autolo-
gous serum. Lymph node cells (LNC; 4 × 105 per 200 µl
per well) were plated in 96-well flat-bottomed plates and
stimulated with zymosan at specified concentrations. Con-
canavalin A at 4 µg/ml was used as non-specific mitogen.
The cells were incubated for 48 hours at 37°C in 5% CO2,
then [3H]thymidine (1 µCi per well) was added to the cul-
tures for 18 hours. The cells were harvested, and [3H]thy-
midine uptake was measured with a beta scintillation
counter.
Determination of interferon-γ production in vitro
Culture supernatants from LNC cultured with or without 4
µg/ml zymosan were harvested after 72 hours forAvailable online http://arthritis-research.com/content/7/2/R370
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determination of interferon (IFN)-γ levels. Quantification of
cytokine production was performed with an enzyme-linked
immunosorbent assay (ELISA) kit specific for murine IFN-γ
(Amersham Pharmacia, Dubendorf, Switzerland).
TLR2 immunohistochemistry
Immunohistochemistry was performed with affinity purified
anti-mouse TLR2 antibody (clone 6C2; eBioscience, San
Diego, CA, USA). Specificity of the antibody was tested on
bone marrow cells derived from c57bl/6 TLR2+/+  and
TLR2-/- mice.
Dissected knees were embedded in Tissue-Tek OCT, then
immediately frozen in precooled hexane and stored at -
70°C until use. Sections 7 µm thick were cut on a motor-
driven Leica cryostat with a retraction microtome and a
tungsten carbide knife at a cabinet temperature of -25°C
and mounted on Menzel Super Frost Color glass slides.
Phagocytosis assay
RAW 264.7 cells (5 × 105 to 106 per chamber) were plated
on a Lab-Tek II Chamber Slide system (Nalge Nunc Inter-
national). After adherence, cells were either preincubated
with 100 or 500 µg/ml laminarin [21] for 20 min followed
by the addition of 25 zymosan particles per cell, or laminarin
was co-administrated with zymosan. After incubation for 3
hours at 37°C in 5% CO2, cells were washed twice with
PBS and fixed for 10 min in acetone. Cell-bound and
phagocytosed particles were stained by periodic acid
Schiff, a stain specific for insoluble glucose polymers, and
quantified by light microscopy.
Quantification of IgG levels
Serum levels of total IgG were quantified with ELISA. In
brief, rabbit anti-mouse IgG (Dako, Carpinteria, CA, USA)
was coated on 96-well plates (Nunc, Roskilde, Denmark).
Murine sera from naive and ZIA mice (dilution 1:100,000)
were added and incubated for 2 hours. Secondary alkaline-
phosphatase-linked anti-mouse IgG (Sigma, Buchs, Swit-
zerland) was added and p-nitrophenyl phosphate (Sigma,
Buchs, Switzerland) completed the reaction.
Serum levels of specific anti-zymosan IgG were also quan-
tified by ELISA. Zymosan particles at 1 mg/ml were coated
on 96-well plates and murine sera (dilution 1:100) were
added and incubated for 2 hours. The reaction was devel-
oped as previously described.
Statistical analysis
The Wilcoxon rank sum test for unpaired variables (two-
tailed) was used to compare differences between groups.
The unpaired Student t-test was used to compare the
groups with normally distributed values. A level of P < 0.05
was considered statistically significant.
Results
Zymosan-mediated inflammation in the knee joint is 
biphasic
In experiments on WT C57bl/6 mice, we observed a bipha-
sic course of inflammation, with an initial peak of 99mTc
uptake at day 1 (1.71 ± 0.08), followed by a decrease to a
trough value at day 7 (1.29 ± 0.05) and a secondary
increase in uptake at day 14. Inflammation measured by
99mTc uptake persisted up to day 25 (1.40 ± 0.06) (Fig.
1a).
Histological assessment of the mice at day 8 showed a low
score for cellular infiltration (1.00 ± 0.32) and for cartilage
destruction (0.7 ± 0.2) (Fig. 1b), whereas scoring at day 25
was characterized by an increase in cellular infiltration (2.5
± 0.37) while cartilage destruction remained low (0.71 ±
0.24) (Fig. 1c).
Histology and immune responses at day 25 of ZIA
To determine whether zymosan particles persisted in the
joint at day 25, periodic acid Schiff staining was performed
on joint tissues obtained at day 25 and showed persistence
of zymosan particles in the synovial membrane of mice
injected with zymosan (Fig. 2a).
To verify that joint inflammation was associated with the
development of specific immune responses to zymosan, we
assessed both humoral and cellular responses in WT mice.
Proliferation of LNC in response to zymosan was signifi-
cantly increased in day 25 WT ZIA mice compared with
LNC of naive mice (3.5 stimulation index in ZIA WT mice
versus 1.5 in naive mice; P < 0.001), whereas mitogenic
response to the non-specific mitogen concanavalin A at 4
µg/ml showed no difference between groups (Fig. 2b). No
difference in proliferation in response to zymosan was
observed between ZIA and naive mice at day 8 (data not
shown).
The humoral response to zymosan was measured by
ELISA. In arthritic mice, the serum levels of anti-zymosan
IgG antibodies were significantly increased at day 25 in
comparison with those in untreated naive mice (antibody
ratio for WT = 0.944 versus naive = 0.677; P < 0.02) (Fig.
2c).
In addition, in vitro stimulation of WT ZIA LNC with
zymosan at 4 µg/ml induced the secretion of IFN-γ at 1200
pg/ml, whereas unstimulated LNC produced undetectable
levels of IFN-γ (Fig. 2d).
Synovial expression of TLR2 and its role in ZIA
We wished next to evaluate whether TLR2 might have a
role in the recognition of zymosan in vivo and in mediating
inflammation in ZIA. Specific antibody for TLR2 was used
to stain synovium from WT mice that had developed ZIA atArthritis Research & Therapy    Vol 7 No 2    Frasnelli et al.
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day 25. Figure 3a shows a representative example of the
distribution of TLR2 expression in the synovial cell lining.
Control antibody staining was negative (Fig. 3b). Antibody
specificity was confirmed by a lack of staining in TLR2-/-
mice (data not shown).
To explore whether the deficiency of TLR2 had an effect on
the course of ZIA, we measured knee joint inflammation in
TLR2+/+ and TLR2-/- mice by 99mTc uptake at different time
points up to day 24 (Fig. 3c). In two independent experi-
ments we observed an attenuation of inflammation in TLR2-
/- mice at days 1, 3, 14, 17 and 24, although only the
decrease observed at days 1 and 24 reached statistical
significance (P < 0.05).
TLR2 deficiency ameliorates histological features of ZIA
We compared the histological features of arthritic knee
joints from TLR2+/+ and TLR2-/- mice (Fig. 3d). In both
groups, arthritis was histologically present in all knees that
had been injected with zymosan. In TLR2+/+ mice, on day
25 of ZIA, the synovial membrane was thickened, mainly as
a result of invasion by inflammatory cells (see Fig. 1c). In
TLR2-/- mice, synovial infiltrate was significantly decreased
in comparison with TLR2+/+ mice (4.9 ± 0.33 in TLR2+/+
mice [n = 15] versus 3.1 ± 0.67 in TLR2-/- mice [n = 12] on
day 25 after arthritis onset; P < 0.045).
TLR2-/- mice showed no difference from WT mice in terms
of cartilage destruction, as assessed by the loss of
safranin-O staining at day 25 (Fig. 3d).
Effect of TLR2 deficiency on cellular responses
The role of TLR2 on the cellular response to zymosan was
examined by isolating LNC from ZIA mice. The proliferation
of LNC induced by zymosan was significantly lower in cells
isolated from TLR2-/- mice than in TLR2+/+ mice. A signifi-
cant difference was found at both concentrations of
zymosan studied (4 and 8 µg/ml; both P < 0.05) (Fig. 3e).
No differences were observed in proliferation stimulated by
the non-specific mitogen concanavalin A (data not shown).
The serum levels of anti-zymosan IgG antibodies, measured
by ELISA, were decreased by 50% in TLR2-/- mice at day
25 in comparison with the serum levels in controls (anti-
body ratio for WT = 1.00 versus TLR2-/- = 0.51, P = 0.047)
(Fig. 3f).
Figure 1
Biphasic kinetic of inflammation in zymosan-induced arthritis (ZIA) Biphasic kinetic of inflammation in zymosan-induced arthritis (ZIA). (a) 99mTc uptake measurement shows a biphasic course of inflammation in wild-
type (WT) mice. Zymosan was injected into the right knee and PBS was injected into the contralateral control knee. The values obtained correspond 
to the ratio between the right and left knee (n = 15). The severity of histological signs of arthritis was assessed by scoring synovial thickness and 
cartilage destruction on a scale from 0 to 6. Results are expressed as means ± SEM. (b) WT mice with ZIA showed mild inflammation at day 8 as 
judged by cellular infiltration (histological score 1.00 ± 0.32) and cartilage destruction (0.7 ± 0.2; n = 10), which became more severe at day 25. (c) 
There was an increase in cellular infiltration (2.5 ± 0.37) but cartilage destruction remained slight (0.71 ± 0.21; n = 10). The arrows in (b) and (c) 
indicate inflammatory infiltrate in the synovial membrane.
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Lack of effect of C3 on inflammation in ZIA
The availability of C3-deficient mice in a C57bl/6 back-
ground allowed us to reassess the role of C3 in ZIA. No
effect, either in 99mTc uptake or in histological scoring, was
observed in C3-deficient (n = 25) mice in comparison with
WT mice (n  = 25). In addition, humoral and cellular
responses were similar in C3-/- and C3+/+ mice (data not
shown).
Generation of TLR2/C3 double-deficient mice gave similar
responses as TLR2-/- mice, excluding a synergistic effect of
double deficiency and confirming no role for the alternative
pathway component of the complement cascade (Fig. 4a).
Histological scoring showed the presence of arthritis in
both groups of animals. In TLR2/C-3 double-deficient mice,
synovial infiltrate was significantly decreased in compari-
son with control (4.0 ± 0.65 in control mice [n = 5] versus
1.9 ± 0.62 in TLR2/C-3 double-deficient mice [n = 5] on
day 25 after arthritis onset; P < 0.05) (Fig. 4b).
TLR2/C-3 double-deficient mice also showed a signifi-
cantly decreased cartilage destruction in comparison with
WT mice at day 25 (1.7 ± 0.12 in control mice [n = 5] ver-
sus 0.9 ± 0.29 in TLR2/C-3 double-deficient mice [n = 5];
P < 0.05) (Fig. 4b).
Stimulation of LNC with zymosan in vitro showed a signifi-
cant decrease of stimulation in double-deficient mice com-
pared with WT littermates, similar to that observed in TLR2-
/- mice (data not shown).
In addition, a decreased production of zymosan-specific
IgGs was observed in the double-deficient mice (ratio for
WT = 0.944 versus double knockout = 0.616; P < 0.05)
(Fig. 4c).
Dectin-1 has a minor role in inflammation in ZIA
The identification of the β-glucan receptor Dectin-1 and its
ability to bind zymosan particles in vitro stimulated us to
study the role of Dectin-1 in vivo in ZIA. In vitro blockade of
the Dectin-1 receptor by laminarin led to a 50% decrease
in a phagocytosis assay with RAW 264.7 cells. This
decrease was not dependent on the time of administration
of laminarin, because it was not modified by preincubation
or co-incubation with zymosan particles (Fig. 5a).
Co-administration of laminarin and zymosan in the knee
joint of C57bl/6 mice showed a trend to a decrease of
99mTc uptake in the early phase of inflammation in a lami-
narin-treated knee, compared with an untreated knee, at 4
hours and 1 day after administration, but did not reach sta-
tistical significance (Fig. 5b).
Figure 2
Local and immune responses to zymosan at day 25 Local and immune responses to zymosan at day 25. (a) Periodic acid Schiff staining shows the persistence of zymosan particles (arrow) within the 
synovial membrane in zymosan-induced arthritis (ZIA). Original magnification ×100. (b) In vitro lymph node mononuclear cell proliferation in 
response to zymosan at day 25 of ZIA and in naive mice. Single-cell suspensions were incubated with 4 µg/ml zymosan. Concanavalin A (ConA) 
was used as a non-specific mitogen. (c) Antibody production against zymosan in zymosan-treated mice compared with naive mice measured by 
enzyme-linked immunosorbent assay (ELISA). The results are expressed as a ratio of the amount of zymosan-specific IgGs (in arbitrary units) in 
murine serum to total IgGs (also in arbitrary units) (P < 0.05). (d) Interferon-γ (IFN-γ) production by zymosan-stimulated and unstimulated lymph 
node cells of WT ZIA and naive mice in culture. IFN-γ was measured by specific ELISA. n.d., not detectable.
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Discussion
For more than 50 years zymosan has been a tool in the
study of microbial recognition by the innate immune sys-
tem. The mechanisms mediating the recognition and
phagocytosis of zymosan in vivo are complex. Phagocytes,
including monocytes, macrophages and dendritic cells,
express receptors such as the TLRs, complement receptor
3, scavenger receptors (such as acetylated LDL receptors)
and Dectin-1 [22-24], which have all been implicated in the
cellular response to zymosan [25]. In addition, zymosan is
capable of activating the alternative pathway of comple-
ment through C3 [3], which may serve to amplify the inflam-
matory response.
To elucidate how zymosan induces inflammation in vivo, we
re-investigated the ZIA model that was first studied in the
1970s. This model has been often used as a tool to dissect
non-immune mechanisms of joint inflammation [26-28]. In
our experiments we observed that ZIA was not as short
lived as originally described. Arthritis persisted beyond day
14 and in fact beyond day 25. After an initial peak of inflam-
mation at about day 3, inflammation subsided by day 7.
Subsequently, inflammation returned to levels that could be
as high (as measured by 99mTc uptake) as the initial peak,
suggesting that ZIA has early and late phases. Histologi-
cally, the joint inflammation was characterized by
mononuclear cell infiltration in the sublining layer and
hypertrophy of the lining layer as well as cartilage damage.
Histological changes were milder at day 8 than at day 25.
Zymosan particles were present in the synovium at day 25.
We then investigated the role of TLR2 in ZIA because the
macrophage inflammatory response to zymosan depends
largely on its recognition by a heterodimer of TLR2 and
Figure 3
TLR2 mediates an inflammatory response in zymosan-induced arthritis (ZIA) TLR2 mediates an inflammatory response in zymosan-induced arthritis (ZIA). (a) Immunohistochemistry of TLR2 expression in synovial membrane 
sections of WT mice (day 25 ZIA) showed staining in the sublining (sl) of synovial membrane, whereas inflammatory lymphocytes were not stained. 
(b) Negative control was performed with 0.5% bovine serum albumin. (100× magnification). (c) 99mTc uptake measurement showed an attenuation 
of the inflammatory response at days 1 and 25 (P < 0.05) in TLR2-/- ZIA mice (n = 5) compared with WT ZIA mice (n = 5). The technetium ratio was 
measured as detailed in the Materials and methods section. (d) Histological scoring at day 25 of ZIA showed a significant decrease in cell infiltration 
in TLR2-/- mice (P < 0.02) compared with control mice, whereas cartilage destruction was similar in both groups. (e) Lymph node cell proliferation to 
4 and 8 µg/ml zymosan (Zym 4 and Zym 8, respectively). (f) Antibody production against zymosan in zymosan-treated TLR2+/+ and TLR2-/- mice.
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TLR6 [2,10]. In TLR2-/- mice there was a significant attenu-
ation of the early and late inflammatory phases of ZIA,
indicating that a ligand that activates the innate immune
response through TLR2 can lead to a chronic local inflam-
matory reaction.
In the absence of TLR2, joint inflammation was not totally
blocked. This would suggest that, in vivo, the inflammatory
response to zymosan is not dependent on TLR2 signalling
alone and that receptors other than TLR2 might have a role.
This is supported by the observation that inhibition of TLR2
and MyD88 by dominant-negative mutants blocked pro-
inflammatory signalling but not zymosan uptake in vitro.
Recent data have shown that Dectin-1 and SIGNR1 [29]
on macrophages and pentraxin-3, an opsonin for the recog-
nition of zymosan by Dectin-1, are involved in zymosan rec-
ognition and internalization [30]. We therefore investigated
the role of Dectin-1 by using the β-glucan laminarin as a
competitive inhibitor of zymosan [16]. We confirmed that
laminarin inhibited zymosan uptake by RAW 264.7 cells
and did not observe any difference in the blocking capacity
of laminarin, whether administered before or at the same
time as zymosan. In both cases and at two different con-
centrations, we observed a 50% decrease in cell-bound
zymosan particles. On the basis of these results, we pro-
ceeded to assess the effect of laminarin on ZIA. Although
there was a trend towards reduced 99mTc uptake in the
treated animals, this was not statistically significant. It is
possible that 50% inhibition of zymosan phagocytosis is
insufficient to modulate inflammatory signalling through
TLR2. Furthermore, a redundancy in the multiple mecha-
nisms that mediate zymosan phagocytosis could also
explain the lack of effect of laminarin inhibition in vivo [31].
The biphasic course of ZIA and its modulation by TLR2 led
us to study the acquired immune response to zymosan and
the effects of TLR2 deficiency on it. We compared the cel-
lular proliferative and antibody responses to zymosan in WT
and TLR2-/- mice at day 25. First, we were able to detect
zymosan-induced lymphocyte proliferation and enhanced
IFN-γ production in the draining LNC of mice with ZIA, and
second, this was accompanied by the formation of a
zymosan-specific IgG. In TLR2-/- animals, the proliferative
response was blunted and only reached 50% of that
observed in WT ZIA animals. There was also a significant
decrease in the zymosan-specific IgG response, which was
about 50% lower than in WT mice. At day 8 we did not
observe any difference between ZIA and naive WT mice in
Figure 4
C3 has no role in mediating inflammatory responses in zymosan-induced arthritis C3 has no role in mediating inflammatory responses in zymosan-induced arthritis. (a) 99mTc uptake measurement showed an attenuation of inflamma-
tion at early and late time points in TLR2/C3 double-deficient (KO) mice (n = 5) compared with double wild-type (WT) mice (n = 5) but did not reach 
statistical significance. (b) Histological scoring showed a significant decrease in both cell infiltration (P < 0.05) and cartilage destruction (P < 0.05) 
in TLR2/C-3 double-deficient mice (n = 5) compared with littermate control (n = 5). (c) Production of specific anti-zymosan IgGs was reduced in 
double-deficient mice in comparision with double WT littermates. Values correspond to the ratio of zymosan-specific IgG to total IgG mentioned in 
Fig. 2c.
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their proliferative response to zymosan (data not shown).
These findings suggest that inflammation in the later phase
of ZIA is paralleled by the development of acquired immune
response to zymosan. The finding that zymosan particles
persisted in the joint even at day 25 suggests that they
could become a target for specific immune responses. The
decrease in acquired immune responses in TLR2-/- mice
might be a result of the decreased antigen presentation
efficiency of dendritic cells in the absence of TLR2 [32] or
the lack of co-stimulatory signals through TLR2 expressed
on activated T cells [33].
A significant role for the alternative pathway of complement
in this model of inflammation was excluded by the pheno-
type observed in C3-/- mice. Both phases of ZIA were com-
parable to that observed in WT controls. Mice with
combined deletions of the C3 and the TLR2 genes did not
show a significant decrease in 99mTc uptake in comparison
with TLR2-/- mice. Histologically, we observed a significant
decrease in cartilage damage in mice with the combined
deficiency of TLR2 and C3, which did not occur in C3-/-
mice. We interpret this effect to be due in principle to the
lack of TLR2, because TLR2-/- mice also showed a dimin-
ished cartilage score (although it did not reach statistical
significance). Combined with recent data showing that
phagocytosis of zymosan is not mediated by complement
receptor 3 [16], complement activation does not seem to
contribute to zymosan-induced joint inflammation in vivo.
The expression of TLR2 in arthritic synovium from WT mice
in the ZIA model and the modulation of joint inflammation in
TLR2-/- animals show that TLR2 may have a general role in
amplifying local inflammation. TLR2 has been shown to be
expressed on neutrophils and lymphocytes as well as mac-
rophages, and they all are participants in the inflammatory
process in this model. The data in human arthritis would
also support such a role for TLR2. Increased expression of
TLR2 in synovial lining layer and by CD16+ peripheral blood
mononuclear cells in RA indicate that its expression is
upregulated during chronic inflammation [34]. TLR2 is also
expressed on RA synovial fibroblasts, and incubation of cul-
tured RA synovial fibroblasts with pro-inflammatory
cytokines increases levels of TLR2 mRNA [35]. Although
the precise role of TLR signalling in RA is unclear at
present, increased TLR2 expression might modulate syno-
vial inflammation if endogenous or exogenous TLR2 ligands
gain access to the joint, thus amplifying specific and innate
immune pathways of synovial inflammation. Furthermore,
our results provide a model by which stimulation of the
innate immune response can lead to chronic inflammation
in the joint. These pathways may be of relevance to the
development of reactive arthritis in man.
Conclusion
The results of the present study indicate that the biphasic
joint inflammation in ZIA is mediated primarily by activation
of the innate immune system. In the early phase of arthritis
TLR2 plays a vital role, and in the later phase the develop-
ment of a secondary immune response to zymosan may
contribute to joint inflammation. Innate immune responses
may be important amplificatory pathways of joint inflamma-
tion in man.
Figure 5
Dectin-1 inhibition in vitro and in vivo Dectin-1 inhibition in vitro and in vivo. (a) In a phagocytosis assay, 2.5 × 106 particles of zymosan were incubated with 10 × 105 RAW 264.7 cells. 
Laminarin was administered either before (pre adm.) or at the same time as (co adm.) the zymosan particles. Incubation of zymosan particles was 
performed for 4 hours at 37°C. Laminarin decreased the amount of zymosan bound to and phagocytosed by RAW 264.7 cells by 50% in compari-
son with a control to which no laminarin had been added (P < 0.05). (b) Laminarin (500 µg) and zymosan (180 µg) in a final volume of 15 µl were 
co-injected into the right knee joint of C57bl/6 mice (n = 6). Phosphate-buffered saline (15 µl) was injected into the contralateral knee. 99mTc uptake 
was measured up to day 7. Comparison of 99mTc uptake with control mice (n = 8), which received zymosan alone in the right knee, showed an atten-
uation of inflammation at 4 and 24 hours in the laminarin-treated mice, but did not reach statistical significance. After 72 hours the values were 
similar.
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